<DOC>
	<DOCNO>NCT00603642</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety AMG 531 compare placebo thrombocytopenic Japanese subject immune ( idiopathic ) thrombocytopenic purpura ( ITP ) .</brief_summary>
	<brief_title>P3 Study Evaluate Efficacy Safety AMG 531 Thrombocytopenic Japanese Subjects With Immune ( Idiopathic ) Thrombocytopenic Purpura</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Japanese patient diagnosis ITP accord diagnostic criterion propose Research Committee Idiopathic Hematopoietic Disorders Ministry Health , Labour Welfare [ MHLW ] ( revised 1990 ) least 6 month first screen visit The mean 3 schedule platelet count take scheduled visit screen period must ≤ 30 x 10^9/L , individual count &gt; 35 x 10^9/L Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Subjects must ≥ 20 year age time obtain inform consent Have receive least 1 prior treatment ITP If know Helicobacter pylorus positive , complete one course Helicobacter pylori eradication therapy least 12 week first screen visit A hemoglobin value take scheduled visit screen period must ≥ 10 g/dL A serum creatinine concentration take scheduled visit screen period must ≤ 2 mg/dL Adequate liver function , evidence total bilirubin take scheduled visit screen period ≤ 1.5 time upper limit normal range ( except patient confirm diagnosis Gilbert 's Disease ) alanine aminotransferase aspartate aminotransferase take screen visit ≤ 3 time upper limit normal range Any known history bone marrow stem cell disorder . Any abnormal bone marrow finding typical ITP . Any active malignancy . If prior history cancer basal cell carcinoma cervical carcinoma situ , treatment active disease within 5 year first screen visit . Documented diagnosis arterial thrombosis ( eg , stroke , transient ischemic attack , myocardial infarction ) ; history venous thrombosis ( eg , deep vein thrombosis , pulmonary embolism ) receive anticoagulation therapy first screen visit . Documented diagnosis anti phospholipid antibody syndrome Currently receive treatment ITP except oral corticosteroid , azathioprine and/or danazol administer constant dose schedule least 4 week prior first screen visit Received intravenous immunoglobulin , anti D immunoglobulin , drug administer increase platelet count ( eg , immunosuppressant except azathioprine ) within 2 week first screen visit Have splenectomy reason within 12 week first screen visit Past present participation study evaluate pegacaristim ( polyethylene glycolconjugated recombinant human megakaryocyte growth development factor , KRN9000 ) , Eltrombopag ( SB 497115 ) , recombinant human thrombopoietin , AMG 531 , Mpl stimulation product Received hematopoietic growth factor ( eg , granulocyte colony stimulate factor , macrophage colony stimulate factor , erythropoietin , interleukin 11 ) reason within 4 week first screen visit Received anti malignancy agent ( eg , cyclophosphamide , 6 mercaptopurine , vincristine , vinblastine , Interferon alfa ) reason within 8 week first screen visit Received monoclonal antibody drug ( eg , rituximab ) reason within 14 week first screen visit Less 4 week since receipt therapeutic drug device MHLW approve indication first screen visit Pregnant breast feeding Subjects reproductive potential use adequate contraceptive precaution , judgment investigator Known severe drug hypersensitivity Concerns subject 's compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>AMG 531</keyword>
	<keyword>Idiopathic Thrombocytopenic Purpura</keyword>
	<keyword>ITP</keyword>
	<keyword>Thrombocytopenia</keyword>
	<keyword>Japan</keyword>
	<keyword>Placebo control</keyword>
	<keyword>Phase 3</keyword>
</DOC>